The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ISHL12 2022 | The potential role of liquid biopsy in the biological classification of HL
Sven Borchmann, MD, University of Cologne, Cologne, Germany, comments on the current landscape of diagnosis and treatment for patients with Hodgkin lymphoma (HL), highlighting that liquid biopsies may be useful tools for patient risk stratification as they can give detailed information on the tumor genome and microenvironment. This interview took place at the 12th International Symposium on Hodgkin Lymphoma (ISHL12), held in Cologne, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
